Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306685841> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W4306685841 abstract "To investigate the efficacy and safety of buparlisib, an oral pan-PI3K inhibitor, in relapsed or refractory thymomas.This was a single center, single arm, open label phase II trial of buparlisib in patients with recurrent thymoma who have progressed after at least one prior line of treatment. The primary endpoint was objective response rate (complete response [CR] + partial response [PR]). Secondary endpoints included toxicity; progression free survival (PFS); overall survival (OS); disease control rate (DCR), i.e., the percentage of patients who achieve either PR or CR or stable disease [SD] for at least 4 months.Between 10/13/2014 and 1/18/2017, 14 patients with stage IV disease were enrolled. Median age was 58y (23-74). 71% were females and 71% white. All patients had WHO B2 (29%) or B3 (71%) thymoma. Patients received buparlisib for a median of 4.5m (2-33). At a median follow up of 16.6m (2.4-31.3), onr patients (7%) achieved a PR. DCR was 50%. Median PFS was 11.1m (95% CI 2.9 - 18.8). Median OS, updated as of March, 2021 was 22.5m (10.7-31.3). Most common grade 3-4 adverse events related to buparlisib were dyspnea (21%), rash (14%), elevated transaminases (14%), cough (7%), pneumonitis (7%), anxiety (7%), fatigue (7%) and hyperglycemia (7%). Reasons for treatment discontinuation included progression of disease (n= 5), rash (n=4), pulmonary toxicity (n=3), sinusitis (n=1), and disseminated toxoplasmosis plus autoimmune cholangitis (n=1). As of 3/2021, 8 patients have died, 7 due to disease progression and 1 due to central nervous system toxoplasmosis and autoimmune cholangitis.Buparlisib showed modest activity in patients with relapsed or refractory thymomas. Further investigation of PI3K pathway targeted therapy in thymoma is warranted. (clinicaltrials.gov ID: NCT02220855).clinicaltrials.gov, identifier (NCT02220855)." @default.
- W4306685841 created "2022-10-19" @default.
- W4306685841 creator A5006346528 @default.
- W4306685841 creator A5012011099 @default.
- W4306685841 creator A5021904320 @default.
- W4306685841 creator A5024142364 @default.
- W4306685841 creator A5049097819 @default.
- W4306685841 creator A5049263574 @default.
- W4306685841 creator A5080410100 @default.
- W4306685841 creator A5088664989 @default.
- W4306685841 date "2022-10-18" @default.
- W4306685841 modified "2023-10-14" @default.
- W4306685841 title "A phase II study of buparlisib in relapsed or refractory thymomas" @default.
- W4306685841 cites W2016927758 @default.
- W4306685841 cites W2036539460 @default.
- W4306685841 cites W2053244130 @default.
- W4306685841 cites W2070300061 @default.
- W4306685841 cites W2160612042 @default.
- W4306685841 cites W2165581959 @default.
- W4306685841 cites W2168071502 @default.
- W4306685841 cites W2340276940 @default.
- W4306685841 cites W2415082602 @default.
- W4306685841 cites W2613990243 @default.
- W4306685841 cites W2767661899 @default.
- W4306685841 cites W2885496181 @default.
- W4306685841 cites W2896211882 @default.
- W4306685841 cites W2901488820 @default.
- W4306685841 cites W2949916791 @default.
- W4306685841 cites W2952165232 @default.
- W4306685841 cites W2954725071 @default.
- W4306685841 doi "https://doi.org/10.3389/fonc.2022.891383" @default.
- W4306685841 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36330484" @default.
- W4306685841 hasPublicationYear "2022" @default.
- W4306685841 type Work @default.
- W4306685841 citedByCount "4" @default.
- W4306685841 countsByYear W43066858412023 @default.
- W4306685841 crossrefType "journal-article" @default.
- W4306685841 hasAuthorship W4306685841A5006346528 @default.
- W4306685841 hasAuthorship W4306685841A5012011099 @default.
- W4306685841 hasAuthorship W4306685841A5021904320 @default.
- W4306685841 hasAuthorship W4306685841A5024142364 @default.
- W4306685841 hasAuthorship W4306685841A5049097819 @default.
- W4306685841 hasAuthorship W4306685841A5049263574 @default.
- W4306685841 hasAuthorship W4306685841A5080410100 @default.
- W4306685841 hasAuthorship W4306685841A5088664989 @default.
- W4306685841 hasBestOaLocation W43066858411 @default.
- W4306685841 hasConcept C121332964 @default.
- W4306685841 hasConcept C126322002 @default.
- W4306685841 hasConcept C141071460 @default.
- W4306685841 hasConcept C142424586 @default.
- W4306685841 hasConcept C197934379 @default.
- W4306685841 hasConcept C203092338 @default.
- W4306685841 hasConcept C2778570526 @default.
- W4306685841 hasConcept C2778715236 @default.
- W4306685841 hasConcept C2778822529 @default.
- W4306685841 hasConcept C2779134260 @default.
- W4306685841 hasConcept C2779159893 @default.
- W4306685841 hasConcept C29730261 @default.
- W4306685841 hasConcept C31760486 @default.
- W4306685841 hasConcept C535046627 @default.
- W4306685841 hasConcept C71924100 @default.
- W4306685841 hasConcept C87355193 @default.
- W4306685841 hasConcept C90924648 @default.
- W4306685841 hasConceptScore W4306685841C121332964 @default.
- W4306685841 hasConceptScore W4306685841C126322002 @default.
- W4306685841 hasConceptScore W4306685841C141071460 @default.
- W4306685841 hasConceptScore W4306685841C142424586 @default.
- W4306685841 hasConceptScore W4306685841C197934379 @default.
- W4306685841 hasConceptScore W4306685841C203092338 @default.
- W4306685841 hasConceptScore W4306685841C2778570526 @default.
- W4306685841 hasConceptScore W4306685841C2778715236 @default.
- W4306685841 hasConceptScore W4306685841C2778822529 @default.
- W4306685841 hasConceptScore W4306685841C2779134260 @default.
- W4306685841 hasConceptScore W4306685841C2779159893 @default.
- W4306685841 hasConceptScore W4306685841C29730261 @default.
- W4306685841 hasConceptScore W4306685841C31760486 @default.
- W4306685841 hasConceptScore W4306685841C535046627 @default.
- W4306685841 hasConceptScore W4306685841C71924100 @default.
- W4306685841 hasConceptScore W4306685841C87355193 @default.
- W4306685841 hasConceptScore W4306685841C90924648 @default.
- W4306685841 hasLocation W43066858411 @default.
- W4306685841 hasLocation W43066858412 @default.
- W4306685841 hasLocation W43066858413 @default.
- W4306685841 hasOpenAccess W4306685841 @default.
- W4306685841 hasPrimaryLocation W43066858411 @default.
- W4306685841 hasRelatedWork W1971901954 @default.
- W4306685841 hasRelatedWork W2009096079 @default.
- W4306685841 hasRelatedWork W2084219681 @default.
- W4306685841 hasRelatedWork W2116572758 @default.
- W4306685841 hasRelatedWork W2347514276 @default.
- W4306685841 hasRelatedWork W2351476339 @default.
- W4306685841 hasRelatedWork W2356374822 @default.
- W4306685841 hasRelatedWork W3030456012 @default.
- W4306685841 hasRelatedWork W4200278739 @default.
- W4306685841 hasRelatedWork W4206786427 @default.
- W4306685841 hasVolume "12" @default.
- W4306685841 isParatext "false" @default.
- W4306685841 isRetracted "false" @default.
- W4306685841 workType "article" @default.